TransMedics Announces New Employee Inducement Grants Under NASDAQ Rule 5635

TransMedics Group, Inc. (Ticker: TMDX), a prominent player in the medical technology sector, is making headlines with its latest announcement regarding employee inducement grants. On July 28, 2025, the company revealed that it had granted non-qualified stock options totaling 21,458 shares, along with 14,283 restricted stock units to 14 new employees. This initiative aligns with the NASDAQ Listing Rule 5635(c)(4) and is a strategic move to attract and retain talent amidst a competitive job market in the medical field.

The stock options come with a per share exercise price of $105.24, reflecting the closing market price of the company's common stock on the date of the grant. Each employee will have 25% of their granted shares vesting on the anniversary of their employment start date, while the remaining shares will vest in equal monthly installments over three years. This structure incentivizes employees to maintain their commitment to TransMedics while offering them a tangible stake in the company's future success.

In addition to the stock options, TransMedics also approved the granting of restricted stock units (RSUs). Similar to the stock options, 25% of these RSUs will vest over the first four anniversaries of their start date, promoting long-term engagement and loyalty. The awards made under the TransMedics Group, Inc. Inducement Plan are strategically designed to align employee interests with company performance and are subject to continued service requirements.

TransMedics specializes in innovative solutions for organ transplant therapy, focusing on end-stage failure of vital organs such as the heart, lungs, and liver. Founded to confront the pressing need for more viable transplant organs, the company employs cutting-edge technologies for assessing organ viability and preserving quality, which is vital for successful transplant outcomes.

The Company’s Mission

TransMedics is well-regarded for its pioneering work in portable extracorporeal warm perfusion systems. This technology has revolutionized the way donor organs are evaluated and preserved before transplantation, addressing critical issues in the field of organ donation and transplant surgery. The company aims to enhance the quality and utilization of donated organs, thus ensuring improved treatment options for patients suffering from severe organ failure.

The recent inducement grants are a testament to TransMedics' commitment not only to innovation but also to building a dedicated workforce adept at advancing its mission. With a firm grasp on the market dynamics and a clear vision for future growth, TransMedics is strategically positioning itself at the forefront of medical technology.

The compensation committee of TransMedics' Board of Directors reviewed and approved these stock grants, underscoring the importance of aligning employee compensation with shareholder value. As the medical technology landscape continues to evolve, companies like TransMedics will play a crucial role in shaping the future of healthcare through their innovative solutions and dedicated workforce.

TransMedics continues to focus on its goal of increasing the organ donation rate and efficacy of transplants while enhancing the overall survival and health outcomes for patients. By fostering a supportive and rewarding work environment, the company reinforces its reputation as a leader in medical innovation and commitment to patient care. The latest employee inducement measures reflect a proactive approach to retaining talent and promoting long-term growth within the organization.

In summary, TransMedics’ strategic employee inducement grants not only showcase its commitment to fostering talent but also pave the way for increased operational success, ultimately benefiting patients in need of life-saving organ transplants. With ongoing advancements and a passionate team, TransMedics is poised for remarkable achievements in the medical technology field.